Podcast appearances and mentions of david liew

David Liew talks to Linny Phuong, paediatric infectious diseases physician, about changes to prevention and management of respiratory syncytial virus (RSV). They discuss how RSV infections affect communities in Australia, high-risk groups to watch out for, and when to test for RSV. Linny also outlines available RSV immunisations for different populations. Read the full article by Linny and her co-author, David Foley, in Australian Prescriber.

David Liew talks to Claire Larter, a medical officer at the pharmacovigilance branch of the TGA, about her paper on adverse event reporting. Claire explains why pharmacovigilance is important for clinicians, and outlines what type of adverse events should be reported. The conversation also covers the process of reporting adverse events and how the TGA handles reports. Read the full article by Claire and her co-authors in Australian Prescriber.

Is Frequent Lab Monitoring Necessary?:Dr. Bella Mehta The Case for JAKi in PMR:Dr. David Liew Treatment Strategies in RA:Dr. Victoria Konzett What's New in Relapsing Polychondritis?:Dr. Bella Mehta  Worried about CV Risk and JAKi? What about the Steroids?:Dr. David Liew

ACR 24: What I learned in Sjogren's, Takayasu's and CAR-T:Dr. Janet Pope Anti IL-17 on Entheseal Biopsy in PsA:Dr. Eric Dein  axSpA: Impact of TNF and IL-17 in Patients with Prior TNF Exposure:Dr. Brian Jaros Can We Make Clinical Trials Better?:Dr. Janet Pope Cumulative Steroid Use and Cardiovascular Events:Dr. Mrinalini Dey  IL 6 Inhibitors, Frailty and Polymyalgia Rheumatica:Drs. Trish Harkins and Sebastian Sattui IVIG Treatment in Immune-mediated Necrotizing Myopathy:Drs. Caoilfhionn Connolly interviews Dr. Asim Mohamed  Machine Learning for Predicting Flares in axSpA:Dr. Sheila Reyes So really, are JAKs Safe?:Dr. Janet Pope Tackling the Workforce Crisis: A shared dilemma:Drs. Mrinalini Dey,  Louise Pollard and Bharat Kumar The 2024 ACR Guidelines for Lupus Nephritis:Dr. Sheila Reyes  The Real Value of JAKi is Beyond RA:Dr. David Liew  Vaccine Responses:The DMARD Counts:Dr. David Liew

David Liew talks to rheumatologist Nicola Cook about the utility of common investigations for suspected inflammatory arthritis in adults. They discuss the notion of pretest probability and how this is used to determine the utility of testing, and the role of specific tests. Nicola also talks about the potential harm of overinvestigation. Read the full article by Nicola and her co-author, Rachelle Buchbinder, in Australian Prescriber.

Join us as we talk with Dr David Liew about the underappreciated condition of gout, dispell some myths and talk about what's changed in recommendations.  This podcast is in collaboration with Medcast and the Quality Use of Medicines Alliance, a provider of health professional education in Australia focused on the quality use of medicines. Check out their resources here.  Arthritis Australia have further information on gout here. The 2015 study by Philip C Robinson is here An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population 

David Liew speaks with geriatrician and dementia specialist Louise Waite about her article on new and emerging therapies for Alzheimer disease. Louise explains key biomarkers for Alzheimer disease, and the potentially disease-modifying monoclonal antibody therapies that have been approved by the FDA and are now being considered by the TGA in Australia. Read the full article by Louise in Australian Prescriber.

Moderated by Dr. Jack Cush and featuring Drs. Aurelie Najm, David Liew and Jonathan Kay

Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis? Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria: OP0195 Sonelokimab IL 17 A/F nanobody inhibitor LB0005 Izokibep IL17A nanobody inhibitor POS0803 Vunakizumab, another IL17A inhibitor OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib Giant Cell Arteritis and Polymyalgia Rheumatica Update Dr. Janet Pope discusses abstracts LBA0001, OP0233, OP0261 and POS0280 at Eular 2024 in Vienna, Austria. JAK Inhibitors for New Indications Dr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria. Pain in RA: Different Drugs for Different Mechanisms Dr. Aurelie Najm reports from Eular 2024 in Vienna, Austria, about abstracts OP0072 and OP0086. Top 3 Messages About JAK Inhibitor Safety Dr. Janet Pope discusses a debate she participated in at Eular 2024 in Vienna, Austria, and her top three messages regarding JAKi safety. DMARDs and Herpes Zoster Vaccination: To Stop or Not To Stop Dr. Jonathan Kay discusses abstracts POS0620 and OP0020 presented at Eular 2024 in Vienna, Austria. Has JAK POT Hit the Spot About Infection Risk? Dr. Yuz Yusof discusses abstract OP0092 presented at Eular 2024 in Vienna, Austria. Select your GCA Therapy Dr. David Liew discusses LBA0001 presented at Eular 2024 in Vienna, Austria.  

Mechanistic Promise in RA Doesn't Always Mean Actual Gain Dr. David Liew reports on abstracts OP0007 and OP0069 at Eular 2024 in Vienna, Austria. The Role of Psychosocial Determinants in the Management of Rheumatoid Arthritis Dr. Mrinalini Dey reports from Eular 2024 in Vienna, Austria about an abstract she will present during the meeting, POS0309. A Step Closer to Identifying Phenotypes of RA ILD Dr. Mrinalini Dey discusses abstract OP0202 presented at Eular 2024 in Vienna, Austria. Pain in RA: Different Drugs for Different Mechanisms Dr. Aurelie Najm reports from Eular 2024 in Vienna, Austria, about abstracts OP0072 and OP0086. Predicting Palindromic Prognosis Dr. David Liew discusses abstract OP0127 at Eular 2024 in Vienna, Austria. Top 3 Messages About JAK Inhibitor Safety Dr. Janet Pope discusses a debate she participated in at Eular 2024 in Vienna, Austria, and her top three messages regarding JAKi safety. Abatacept Misses on Shingrix Response Dr. David Liew discusses abstract POS0620 at Eular 2024 in Vienna, Austria. Artificial Intelligence Detection of CPPD on Hand Radiographs Dr. Antoni Chan interviews Dr. Thomas Hugle about abstract OP0112 presented at Eular 2024 in Vienna, Austria. Cognitive Function in Older Adults with Lupus Dr. Mrinalini Dey discusses abstract POS0730 presented at Eular 2024 in Vienna, Austria. Difficult-to-treat Rheumatoid Arthritis Validation of the EULAR Definition Dr. Mrinalini Dey discusses abstract OP0156 presented at Eular 2024 in Vienna, Austria. DMARDs and Herpes Zoster Vaccination To Stop or Not To Stop Dr. Jonathan Kay discusses abstracts POS0620 and OP0020 presented at Eular 2024 in Vienna, Austria. Has JAK POT Hit the Spot About Infection Risk? Dr. Yuz Yusof discusses abstract OP0092 presented at Eular 2024 in Vienna, Austria. Inspirations About RA-ILD Dr. Jonathan Kay discusses abstracts POS0070, POS0043 and POS0022 presented at the Eular 2024 meeting in Vienna, Austria. Depression and Anxiety Associated with Inability to Achieve Remission in RA and PsA Dr. Aurelie Najm reports on abstract POS0946 presented at Eular 2024 in Vienna, Austria. Digital Rheumatology Dr. Jonathan Kay reviews abstracts POS0451 and POS0607 presented at Eular 2024 in Vienna, Austria. Drug-resistant RA Does Blinatumomab BiTE? Dr. Yuz Yusof reports on abstract OP0193, presented at Eular 2024 in Vienna, Austria.  

Select your GCA Therapy Dr. David Liew discusses LBA0001 presented at Eular 2024 in Vienna, Austria. DMARDs and Herpes Zoster Vaccination: To Stop or Not To Stop Dr. Jonathan Kay discusses abstracts POS0620 and OP0020 presented at Eular 2024 in Vienna, Austria. Has JAK POT Hit the Spot About Infection Risk? Dr. Yuz Yusof discusses abstract OP0092 presented at Eular 2024 in Vienna, Austria. Depression and Anxiety Associated with Inability to Achieve Remission in RA and PsA Dr. Aurelie Najm reports on abstract POS0946 presented at Eular 2024 in Vienna, Austria. PsA Switch or Cycle, the Eternal Question Dr. Aurelie Najm reports on abstracts POS0278 and POS0266 presented at Eular 2024 in Vienna, Austria. DMARDs and Herpes Zoster Vaccination To Stop or Not To Stop Dr. Jonathan Kay discusses abstracts POS0620 and OP0020 presented at Eular 2024 in Vienna, Austria. Difficult-to-treat Rheumatoid Arthritis Validation of the EULAR Definition Dr. Mrinalini Dey discusses abstract OP0156 presented at Eular 2024 in Vienna, Austria. Has JAK POT Hit the Spot About Infection Risk? Dr. Yuz Yusof discusses abstract OP0092 presented at Eular 2024 in Vienna, Austria. Cognitive Function in Older Adults with Lupus Dr. Mrinalini Dey discusses abstract POS0730 presented at Eular 2024 in Vienna, Austria. Artificial Intelligence Detection of CPPD on Hand Radiographs Dr. Antoni Chan interviews Dr. Thomas Hugle about abstract OP0112 presented at Eular 2024 in Vienna, Austria. Abatacept Misses on Shingrix Response Dr. David Liew discusses abstract POS0620 at Eular 2024 in Vienna, Austria. Inspirations About RA-ILD Dr. Jonathan Kay discusses abstracts POS0070, POS0043 and POS0022 presented at the Eular 2024 meeting in Vienna, Austria. We've Got to Talk about CAR T cells Dr. Yuz Yusof discusses abstract OP0017 presented at the Eular 2024 meeting in Vienna, Austria. Does Withdrawing Steroids Increase Flares in SLE? Dr. Janet Pope reports on abstract OP0180 presented at Eular 2024 in Vienna, Austria. Tapering Treatment for Lupus Dr. Andrea Fava at Eular 2024 in Vienna, Austria, shares his perspectives on several sessions that addressed tapering treatment in lupus. The Crossroads of Autoinflammation and Autoimmunity Dr. Andrea Fava shares his perspectives on autoinflammation and autoimmunity at Eular 2024 in Vienna, Austria. Cognitive Function in Older Adults with Lupus Dr. Mrinalini Dey discusses abstract POS0730 presented at Eular 2024 in Vienna, Austria.

Dr. David Liew discusses abstract POS0620 at Eular 2024 in Vienna, Austria.

Dr. David Liew discusses LBA0001 presented at Eular 2024 in Vienna, Austria.  

Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis? Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria: OP0195 Sonelokimab IL 17 A/F nanobody inhibitor LB0005 Izokibep IL17A nanobody inhibitor POS0803 Vunakizumab, another IL17A inhibitor OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib Transition from Psoriasis to PsA: Can we Prevent It? Dr. Aurelie Najm discusses abstract OP0010 presented at Eular 2024 in Vienna, Austria. JAK Inhibitors for New Indications Dr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria. PsA Treatment: is Earlier Better? Dr. Aurelie Najm discusses abstract OP0184, presented at Eular 2024 in Vienna, Austria. Do MRI changes at the Spine and SI Joints in Treatment of AxSpA Matter? Dr. Eric Ruderman discusses abstracts OP0046 and POS0058 presented at Eular 2024 in Vienna, Austria. OP0046 Effect on SI joint structural lesions with ixekizumab POS0058 Effect on SI joint structural lesions with bimekizumab Does Telemonitoring in SpA Work? Dr. Antoni Chan reports on abstract OP0120 from Eular 2024 in Vienna, Austria. Treat to Target Outcomes in Early AxSpA Dr. Antoni Chan discusses abstract OP0132 presented at Eular 2024 in Vienna, Austria. Potential of Radiomics to Predict TNF Therapy Outcomes in axSpA Dr. Bella Mehta interviews Dr. Vincenzo Venerito about abstract POS0236 at Eular 2024 in Vienna, Austria.   Pain in RA: Different Drugs for Different Mechanisms Dr. Aurelie Najm reports from Eular 2024 in Vienna, Austria, about abstracts OP0072 and OP0086. Top 3 Messages About JAK Inhibitor Safety Dr. Janet Pope discusses a debate she participated in at Eular 2024 in Vienna, Austria, and her top three messages regarding JAKi safety. Giant Cell Arteritis and Polymyalgia Rheumatica Update Dr. Janet Pope discusses abstracts LBA0001, OP0233, OP0261 and POS0280 at Eular 2024 in Vienna, Austria. Does B Cell Depletion Matter? Drs. Yuz Yusof and Ed Vital discuss abstract OP0077 at Eular 2024 in Vienna, Austria. 3 Big Lupus Themes from EULAR 2024 Dr. Janet Pope discusses three hot topics in lupus at Eular 2024 in Vienna, Austria.  Voclosporin and Steroids in Lupus Nephritis Dr. Jack Cush reports on abstract OP0059 presented at Eular 2024 in Vienna, Austria. The Role of Psychosocial Determinants in the Management of Rheumatoid Arthritis Dr. Mrinalini Dey reports from Eular 2024 in Vienna, Austria about an abstract she will present during the meeting, POS0309. Mechanistic Promise in RA Doesn't Always Mean Actual Gain Dr. David Liew reports on abstracts OP0007 and OP0069 at Eular 2024 in Vienna, Austria.   Pain in RA: Different Drugs for Different Mechanisms Dr. Aurelie Najm reports from Eular 2024 in Vienna, Austria, about abstracts OP0072 and OP0086. Top 3 Messages About JAK Inhibitor Safety Dr. Janet Pope discusses a debate she participated in at Eular 2024 in Vienna, Austria, and her top three messages regarding JAKi safety. A Step Closer to Identifying Phenotypes of RA ILD Dr. Mrinalini Dey discusses abstract OP0202 presented at Eular 2024 in Vienna, Austria. Predicting Palindromic Prognosis Dr. David Liew discusses abstract OP0127 at Eular 2024 in Vienna, Austria.

Dr. David Liew discusses abstract OP0127 at Eular 2024 in Vienna, Austria.

Dr. David Liew reports on abstracts OP0007 and OP0069 at Eular 2024 in Vienna, Austria.

David Liew talks to gastroenterologist Varan Perananthan about his article on diagnosis and management of eosinophilic oesophagitis (EoE). Varan explains the causes and symptoms of EoE, why the prevalence has been increasing, and how to differentiate EoE from gastro-oesophageal reflux disease. Also discussed are dietary approaches for identifying food triggers and pharmacological treatments for EoE. Read the full article by Varan and his co-author, Rebecca Burgell, in Australian Prescriber.

Dhineli Perera chats with clinical pharmacologist and fellow podcast host David Liew about Australia's top 10 drugs over the last 2 years. David explains the relationship between the PBAC and the PBS and the different ways the top 10 drugs are presented, and offers some insights into why particular drugs are on the lists. Read the full articles for 2021-22 and 2022-23 in Australian Prescriber.

David Liew talks to Ketaki Sharma, a staff specialist at the National Centre for Immunisation Research and Surveillance, about the latest developments in COVID-19 vaccines and what the future of vaccination looks like in Australia—who needs boosters and which vaccine should they have? Read the full article by Ketaki and her co-author, Jean Li-Kim-Moy, in Australian Prescriber. This interview was conducted on 21 October 2023. The Australian Technical Advisory Group on Immunisation released recommendations on the use of monovalent Omicron XBB.1.5 COVID-19 vaccines on 20 November 2023.

David Liew speaks with infectious diseases physician Ella Meumann. They discuss the latest developments in COVID-19 testing and how the pandemic affected our virus-testing strategies. Read the full article by Ella and her co-author, Jennifer Robson, in Australian Prescriber. This interview was conducted on 28 August 2023.

- PMR is Only Proximal - Drs. Sarah Mackie and David Liew  https://youtu.be/7VpoLT1pXt4?si=zoK96ctYtzKBVrw2 - PMR Needs an Elevated ESR or CRP - Drs. Robert Spiera and David Liew  https://youtu.be/WD8c7HARZig?si=UdJGZkzrlPyvYlrt - PMR Gets 100% Better Within 72 hours - Drs. Eric Matteson and David Liew  https://youtu.be/WxzluNI5gFg?si=zDh6pr2KEWKcjIuG  

A TNR Panel discussion on controversies in PMR: diagnosis, imaging, PCP roles, Lumping vs. Splitting. Featuring Drs. Sarah Mackie, Wolfgang Schmidt, and Len Calabrese. Moderated by Dr. David Liew. Recorded on 10/24/2023

Panel discussion on treatment options beyond steroids in PMR. Featuring Drs. Sebastian Sattui, Sarah Mackie, Anisha Dua, Robert Spiera and David Liew. Recorded on 10/17/2023

Tuesday Nite Rheumatology webinar on the use of corticosteroids in patients with PMR. Featuring panelists, Drs. Lindsey Lally, Richard Conway and Max Yates.moderated by Dr. David Liew. Recorded 10/10/2023

Can patients with rheumatoid arthritis examine their own joints? Dr David Liew talks to Dr Charlotte Sharp and Karen Staniland about their work to create a video teaching patients how to self-examine tender and swollen joints. Charlotte is now a consultant rheumatologist based in Manchester and has an interest in applied health research. Karen is the patient and public involvement lead for the REMORA project and has rheumatoid arthritis. Their paper was a winning entry to the 2023 Rheumatology Advances in Practice Trainee Publishing Programme. Read the article: How to self-examine for tender and swollen joints: co-producing a training video for people with rheumatoid arthritisYou can also watch the video or find out more about the REMORA project. Thanks for listening to Talking Rheumatology Research! Join the conversation on Twitter using #TalkingRheumResearch, tweet us @RheumJnl, or find us on Instagram. Want to read more rheumatology research? Explore Rheumatology and Rheumatology Advances in Practice.

Dhineli Perera talks to Dr David Liew, clinical pharmacologist and rheumatologist, and Elizabeth Su, clinical pharmacist. David and Liz share their experiences working in medicines stewardship and outline the objectives and broad strategies used in stewardship programs. Read the full article in Australian Prescriber.

How can you differentiate between cocaine-induced and ANCA-associated vasculitis? Dr Sander van Leuven joins Dr David Liew to discuss a recent case series analysis from centres in Birmingham and London. Sander is a consultant rheumatologist in Nejmegen, the Netherlands. He previously trained in London, where he conducted a 15-year retrospective study of cocaine-associated pseudovasculitis. Want to find out more? Here's your further reading list:Case series analysis from Gill et al.Sander's accompanying editorial (plus excellent graphic!)Sander's 2018 case series, published in Autoimmunity ReviewsThanks for listening to Talking Rheumatology Research! Join the conversation on Twitter using #TalkingRheumResearch, tweet us @RheumJnl, or find us on Instagram. Want to read more rheumatology research? Explore Rheumatology and Rheumatology Advances in Practice.

Join Drs. Jack Cush, David Liew and Bella Mehta as they recap data presented on Day 4 at EULAR 2023 in Milan, Italy.

Editors Heather Van Epps and Anna Clark join guest hosts Lola Falasinnu, David Liew, and Puja Mehta to reflect on the progress of The Lancet Rheumatology and share their vision for the future. Continue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

David Liew chats with rheumatologist Lyn March and trainee physician Jimmy Zhu about the latest in osteoporosis – how to assess risk, lifestyle factors, and the drugs used to treat.

RheumNow faculty recap the best and most interesting data presented at ACR22 in RA. Panelists: Drs. Richard Conway, Aurelie Najm, David Liew, Janet Pope, Julian Segan

Best of ACR Day Two in PSA Dr. Rachel Tate, discusses abstracts 1018, 1159 at ACR22 Convergence. Comorbidities in Ankylosing Spondylitis Dr. Akhil Sood discusses Abstract 1609 at ACR22 Convergence. Fat and bone are never alone: osteoporotic fracture in RA Dr. David Liew discusses Abstract 889 at ACR22 Convergence.  Abstract 889: Serum Adipokines Predict Incident Osteoporotic Fracture in Patients with Rheumatoid Arthritis GCA: What we feel and what we can't Dr David Liew discusses Abstracts 0483 and 0486 at ACR22 Convergence. Hydroxychloroquine: Cumulative Doses and Thresholds Dr. Sheila Reyes discusses Abstracts 0982 and 0344 at ACR22 Convergence. JAK inhibitors in rheumatic diseases Dr. Antoni Chan discusses abstracts 0510 and 0404 at ACR22 Convergence in Philadelphia, PA. Abstract 0510: MACE and VTE Across Upadacitinib Clinical Trial Programs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis Abstract 0404: Site-Specific Responses of Joint and Entheses to Tofacitinib in Patients with Ankylosing Spondylitis: A Post Hoc Analysis of a Phase 3 Trial Low-grade Proteinuria in Non-Renal Lupus: Should We be Worried? Dr. Yuz Yusof discusses Abstract 1463 presented at ACR22 Convergence in Philadelphia, PA. PET CT Imaging to Define Risk of Progression from PSO to PsA Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence. Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence.  Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes) Tapering TNF Inhib in non Radiolgraphic AxSpA Dr. Peter Nash, Philadelphia Vaccines Work! Dr. Eric Dein and Dr. Caoilfhionn Connolly discuss abstracts 2275 & 0797 at ACR22 Convergence.

Comorbidities in Axial Spondyloarthritis Dr. Antoni Chan discusses Abstract 1609 at ACR22 Convergence. Diffuse alveolar hemorrhage in antiphospholipid syndrome Dr. Eric Dein discusses Abstract 0675 at ACR22 Convergence. Abstract 0675: Clinical Characteristics and Factors Associated with Relapse and Mortality in Diffuse Alveolar Hemorrhage Among Patients with Antiphospholipid Syndrome: A Multi-Center Retrospective Cohort Eosinophilia in systemic JIA patients after exposure to biologics Dr. Bella Mehta discusses Abstract 0872 at ACR22 Convergence. Abstract 0872: Incidence, Risk Factors, and Outcomes of Eosinophilia on IL-1 and IL-6 Inhibitors in Systemic and Non-Systemic Juvenile Idiopathic Arthritis Gender differences in Axial Spondyloarthritis Dr. Antoni Chan covered abstracts 0497 and 1614 at ACR22 Convergence in Philadelphia, PA. Inadequate Dosing of Hydroxychloroquine Leads to Hospitalizations in SLE Dr. Sheila Reyes discusses abstract 1654 at ACR22 Convergence.  Abstract 1654: Hydroxychloroquine Dosing Less Than 5 Mg/kg/day Leads to Increased Hospitalizations for Systemic Lupus Erythematosus Flares Oligoarticular PsA: FOREMOST Study Dr. Peter Nash discusses abstract 1018 at ACR22 Convergence.  Abstract 1018: Characterization of Joint Distribution and Disease Burden in Patients with Early Oligoarticular Psoriatic Arthritis: Results from the Ongoing FOREMOST Study Sensor-engineered glove evaluates hand function in RA Dr. David Liew discusses abstract 0904 at ACR22 Convergence.  Abstract 0904: Testing the Hand Function with a Sensor-engineered Glove in Patients with Rheumatoid Arthritis

Best of PsA on Day 1 Dr. Rachel Tate discusses the best PSA data presented Saturday, November 12, 2002 at ACR22 Convergence.  Abstract 0387: Sleep Quality in Patients with Psoriatic Arthritis and Its Relationship with Activity and Comorbidity Abstract 0377: Differences in Early-onset vs. Late-onset Psoriatic Arthritis: Data from the RESPONDIA and REGISPONSER Studies Can computers tell the difference between RA & PsA? Dr. David Liew discusses Abstract 0242 presented at ACR22 in Philadelphia, PA. Abstract 0242: Neural Networks for Distinguishing Rheumatoid Arthritis from Psoriatic Arthritis by Using Magnetic Resonance Imaging Can you use the BASDAI in Pregnancy? Dr. Eric Dein discusses abstract 0374 presented at ACR22 Convergence in Philadelphia, PA. Abstract 0374: The BASDAI Index During Pregnancy Drs Tate and Worthing What's going on on the Hill Session # 12S119. Effect of voclosporin in class V lupus nephritis Dr. Yusof discusses abstract 0355 presented at ACR22 Convergence in Philadelphia, PA.  Abstract 0355: Long-term Use of Voclosporin in Patients with Class V Lupus Nephritis: Results from the AURORA 2 Continuation Study Microbiome and AxSPA Dr. Akhil Sood discusses abstract 1162 presented at ACR22 Convergence in Philadelphia, PA.  Abstract 1162: Improvement of Gut Microbiota Dysbiosis in Patients with Axial Spondyloarthritis After One Year of Biological Treatment Opioids and Health Care Utilization in PsA and AS Dr Aurelie Najm  discusses Abstract 0402 presented at ACR22 Convergence in Philadelphia, PA. Abstract 0402: Opioid Use and Healthcare Utilization in Adults with PsA and AS Switching Between JAK Inhibiters in RA Dr. Janet Pope discusses abstract 0274 presented at ACR22 Convergence in Philadelphia, PA.  Abstract 0274: Real-world Utilisation and Switching Between Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis in the Australian OPAL Dataset Treatment Choices and Mortality in RA ILd 2 Dr. Julian Segen, Philadelphia Dr. Bryant England, Philadelphia Upadacitinib vs  Adalimumab in PsA using RAPID3 Dr. Catherine Sims discusses abstract 0192 presented at ACR22 Convergence.  0192: Upadacitinib versus Adalimumab on Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Psoriatic Arthritis      

Can we alter neonatal gut microbiome to prevent spondyloarthritis? Dr Chao discusses Abstract 0868 at the ACR22 Convergence meeting.  Abstract 0868: Spondyloarthritis and Neonatal Factors Affecting the Gut Microbiome JAK vs TNF inhibitor Infections in RA Dr. David Liew discusses abstract 0302 at ACR22 Convergence. Abstract 0302: Risk of Infections Between JAK Inhibitors and TNF Inhibitors Among Patients with Rheumatoid Arthritis Opioid and Neuropathic Use After Initiating btsDMARDs in RA Dr. Julian Segan discusses Abstract 0925 at the ACR22 Convergence meeting. The Dietary Intervention in PsA (DIPSA) StudyDr. Patricia Harkins talks with Professor Lihi Eder about abstract 1007 at the ACR22 Convergence meeting.  Abstract 1007: Metabolic Disorders and Abnormal Dietary Patterns and Their Association with Psoriatic Arthritis Activity: The Dietary Intervention in PsA (DIPSA) Study Treatment Considerations in Axial Spondyloarthritis Dr. Lianne Gensler discusses treatment considerations in Axial SpA. Abstract 0402: Opioid Use and Healthcare Utilization in Adults with PsA and AS Abstract 0388: Incidence Rate and Factors Associated with Fractures Among Older Adults with Ankylosing Spondylitis in the United States Abstract 0544: Bimekizumab Improves Signs and Symptoms, Including Inflammation, in Patients with Active Non-Radiographic Axial Spondyloarthritis: 24-Week Efficacy & Safety from a Phase 3, Multicenter, Randomized, Placebo Controlled Study Abstract 0545: Continuing (Full or Reduced Treatment) versus Withdrawing from Golimumab Treatment in Patients with Non-radiographic Spondylarthritis Who Achieved Inactive Disease: Efficacy and Safety Results from a Placebo-Controlled, Randomized Withdrawal and Retreatment Study (GO-BACK) What lifestyle factors affect TNF inhibitor efficacy in AxSpA? Dr Chao discusses Abstract 1510 at ACR22 Convergence. Abstract 1510: Modifying Lifestyle Factors May Offer the Potential to Enhance the Outcome of Tumour Necrosis Factor Inhibitors in Axial Spondyloarthritis – Data from 14 European Countries    

Dr Shirin Heidari, Prof James Wason, Dr Karen Schreiber, and Prof Cheryl Barnabe join guest host Dr David Liew to discuss how sex and gender impact research design and reporting and improvements that can be made.Learn more:The Lancet Summit: Sex and gender in rheumatology

Agarwood or also known as “The Wood of the Gods” is one of the most expensive fragrant dark resinous components of the Aquilaria tree. This unique resin is in high demand as it is used in the medicinal, jewellery, fragrance and essential oil industries. Currently, the agarwood market trade is estimated to be valued at USD32 billion and expected to double to USD64 billion by the end of 2029 globally - making Agarwood the world's most valuable plant species. David Liew and Adrieent Tan share how technology is helping them lead the way in agarwood inoculation.Image Credit: DAdvance Agarwood Solutions Facebook Page

Agarwood or also known as “The Wood of the Gods” is one of the most expensive fragrant dark resinous components of the Aquilaria tree. This unique resin is in high demand as it is used in the medicinal, jewellery, fragrance and essential oil industries. Currently, the agarwood market trade is estimated to be valued at USD32 billion and expected to double to USD64 billion by the end of 2029 globally - making Agarwood the world's most valuable plant species. David Liew and Adrieent Tan share how technology is helping them lead the way in agarwood inoculation.Image Credit: DAdvance Agarwood Solutions Facebook Page

David Liew chats with Jo-Anne Manski-Nankervis about using technology to bring clinical guidelines into practice, removing some of the barriers to their use.

Greta Lindenmayer, Stephen Brady, and Onika Paolucci join guest host David Liew to discuss specialist considerations for the care of Australian Aboriginal patients with lupus.

Patients with obesity often need help with hunger suppression to maintain the weight loss achieved by diet. What drugs are used, and how do they work? David Liew chats with obesity clinician Professor Joseph Proietto.

Prof Peter Taylor (Oxford, UK) joins Dr David Liew to discuss results from the PERSIST study, a real-world, observational, prospective cohort study of CT-P13 for treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Read the paper here: https://doi.org/10.1093/rap/rkab026This episode was originally published in December 2021. 

When and for whom should home oxygen therapy be prescribed, and what is the evidence behind it? David Liew chats with respiratory physician Christine McDonald.

What are the issues surrounding rational prescribing of oral antivirals for COVID-19? David Liew chats with clinical pharmacist Amy Legg and infectious diseases physician Andrew Henderson.

David Liew talks with clinical pharmacology registrar Gloria Wong about some of the challenges involved in the pharmacological management of chronic non-cancer pain in frail older people.

Dr. Dzifa Dey joins guest host Dr. David Liew to discuss innovations in providing specialist rheumatology care and patient education in Ghana, and how her experiences in Africa could help inform development of rheumatology care in other low-resource settings.

David Liew talks to haematologist Cecily Forsyth about this common yet under-recognised condition that can cause a range of non-specific symptoms such as lethargy, irritability and restless legs.

Does RA Begin in the Gut? with Dr. Jonathan Kay Dr. David Liew: 11 Ways to Stay Away From RA Dr. David Liew: Tired of Doing Nothing About Fatigue Lung Now with Drs.  Pope and Sparks Perspectives on TNF and RA Day 1 with Dr. Jon Giles

Does RA Begin in the Gut? with Dr. Jonathan Kay Dr. David Liew: 11 Ways to Stay Away From RA Dr. David Liew: Tired of Doing Nothing About Fatigue Lung Now with Drs. Pope and Sparks Perspectives on TNF and RA Day 1 with Dr. Jon Giles

David Liew talks to Rob Moulds about the challenges facing rational prescribing and quality use of medicines in Australia today.

In episode 1 of "The Limbic" podcast series for rheumatology for advanced trainees, we're excited to introduce the brilliant Dr David Liew and Dr Tina Racunica on biologics. 

David Liew chats with infectious diseases physician Dr Gregory Dore about the strategies required to achieve elimination of hepatitis C in Australia by 2030.

David Liew talks to anaesthetist and pain medicine physician Gavin Pattullo about managing patients’ pain once they are discharged from hospital after surgery.

‘An ounce of prevention is worth a pound of cure.’ David Liew chats with infectious diseases physician Kristine Macartney about the latest on the COVID-19 vaccination program in Australia.

Staying on Therapy in RA: Dr. Janet Pope What is the SEAMless transition from combination Etanercept to Methotrexate? Dr. Jonathan Kay RWCS 2021, Maui. Mark Your Calendar! with Dr. Arthur Kavanaugh Treatment of Dermatomyositis Studies: Dr Robert Chao Combo Therapy v Monotherapy (SEAM-RA Trial): Dr. Richard Conway Treat to Target in Spondyloarthritis: Dr. Rachel Tate XRay Bone Erosions in CCP+ Patients: Dr Eric Dein Impact of Exercise on Sleep: Dr. Kathryn Dao Warfarin and End-Stage Osteoarthritis: Dr. David Liew

Josh Sigurdson talks with Tim Picciott, The Liberty Advisor about the massive scandal that's plagued Deutsche Bank for years.  As we reported years ago, David Liew who is currently on trial exposed a culture of gold market rigging/spoofing at Deutsche Bank after his arrest.  Now he's back in the news and has made some stunning statements about the rigging happening at the embattled German bank. He says that it was so common place at Deutsche Bank to manipulate gold markets that he didn't realize it was wrong.  This has been a topic that has driven many gold and silver investors crazy for years. The markets have been completely suppressed. In fact they're not even meant for investing, they're meant as wealth insurance, however banks like Deutsche Bank, HSBC, Scotia Bank, JP Morgan and BNP Paribas have been infamous for rigging both the gold and silver markets in order to turn a wealth insurance into a quick investment.    You can view this content on Youtube at https://www.youtube.com/watch?v=QB3Anb7DQm8 or LBRY at https://lbry.tv/@WAM:0/deutsche-bank-gold-rigging-scandal-what:3  For more from Tim Picciott please use the links below: Join the conversation in Tim's Discord community: https://discord.gg/vkxUkqg  Itunes: https://bit.ly/libertyadvisor   Lbry.tv https://lbry.tv/$/invite/@thelibertyadvisor:2   Livestreams at https://flote.app/TheLibertyadvisor   Bitchute https://www.bitchute.com/accounts/referral/thelibertyadvisor/   Learn more about Tim's services: www.thelibertyadvisor.com   Free 15 min Investing Consultation www.bit.ly/booktimp   Subscribe to our emergency text list and receive a free ebook “How it's Rigged – The Economy” Text LibertyAdvisor (one word, no spaces) to 71441

Drs. Len Calabrese, David Liew, Sarah Mackie and Jack Cush discuss vasculitis highlights focused on GCA and PMR at EULAR2020 Virtual Conference

Dr. David Liew from EULAR2020 Virtual Conference Early Patient Referrals Preclinical RA patients

Dr. David Liew from EULAR2020 Virtual Conference RA beyond the joints - Tenosynovitis as a predictor, MRI and muscle changes in RA

Dr. David Liew from EULAR2020

David Liew interviews Dr Chamara Basnayake about irritable bowel syndrome and how consultation is key to managing this common disorder.

David Liew interviews Dr Paul Kubler on the pros and cons of fast-tracked approvals for new drugs – does it save patients or put their safety at risk?

David Liew interviews Dr Bridin Murnion about neuropathic pain – what’s changed and why are opioids relegated to third-line treatment?

David Liew interviews Professor Helen Reddel about the cost of asthma inhalers and implications for adherence.

Dr Andrew Boyden interviews Dr David Liew about the aetiology, pathophysiology and management of polymyalgia rheumatica.

Dr David Liew interviews clinical pharmacologist Darren Roberts about why codeine is being rescheduled to a prescription-only medicine and what the implications are.

Dr David Liew interviews Professor Nick Talley about functional dyspepsia - what is it and how is it managed?

Dr John Dowden, Editor of Australian Prescriber, is interviewed by Dr David Liew about the top 10 drugs in Australia for 2016–17. Find out what has changed in terms of prescription counts and cost to Government over the past 10 years. 

Dr David Liew interviews Professor Greg Kyle about product familiarisation programs – are they medically worthwhile or just a marketing exercise?

Dr David Liew interviews Richard Kwiatek, a rheumatologist from Adelaide, about fibromyalgia and how GPs can help these patients in the community.

Dr David Liew interviews Dr Ingrid Hopper about the management of chronic heart failure. Diagnosing the type of heart failure is critical as it determines treatment.

Dr David Liew interviews Dr Ken Harvey about over-the-counter genetic tests, and whether they are all they promise to be.

Dan and Jane talk to David Liew, a Rheumatologist and Clinical Pharmacology fellow.   We talk to David about: The difference between biosimilars and generic medicines What is currently known about the safety and efficacy of biosimilar products Implications for pharmacists dispensing biosimilar medicines